https://scholars.lib.ntu.edu.tw/handle/123456789/566455
標題: | A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 month of age | 作者: | Pavia-Ruz N. Weber M.A.R. Lau Y.-L. Nelson E.A.S. Kerdpanich A. LI-MIN HUANG Silas P. Qaqundah P. Blatter M. Jeanfreau R. Lei P. Jain V. El Idrissi M. Feng Y. Innis B. Peeters M. Devaster J.-M. |
關鍵字: | Children; Immunogenicity; Influenza; Trivalent inactivated; Vaccine | 公開日期: | 2013 | 卷: | 9 | 期: | 9 | 起(迄)頁: | 1978-1988 | 來源出版物: | Human Vaccines and Immunotherapeutics | 摘要: | The trivalent inactivated influenza vaccine Fluarix? is licensed in the US for adults and children from 3 years old. This randomized observer-blind study (NCT00764790) evaluated Fluarix? at two doses; 0.25 ml (Flu-25) and 0.5 ml (Flu-50) in children aged 6-35 months. The primary objective was to demonstrate immunogenic non-inferiority vs. a control vaccine (Fluzone?; 0.25 ml). Children received Flu-25 (n = 1107), Flu-50 (n = 1106) or control vaccine (n = 1104) at Day 0 and for unprimed children, also on Day 28. Serum hemagglutination-inhibition titers were determined pre-vaccination and at Day 28 (primed) or Day 56 (un-primed). Non-inferiority was assessed by post-vaccination geometric mean titer (GMT) ratio, (upper 95% confidence interval [CI] ? 1.5) and difference in seroconversion rate (upper 95% CI ? 10%). Reactogenicity/ safety was monitored. The immune response to Flu-50 met all regulatory criteria. Indicated by adjusted GMT ratios [with 95% CI], the criteria for non-inferiority of Flu-50 vs. control vaccine were reached for the B/Florida strain (1.13 [1.01-1.25]) but not for the A/Brisbane/H1N1 (1.74 [1.54-1.98]) or A/Uruguay/H3N2 (1.72 [1.57-1.89]) strains. In children aged 18-35 months similar immune responses were observed for Flu-50 and the control vaccine. Flu-50 induced a higher response than Flu-25 for all strains. Temperature (?37.5°C) was reported in 6.2%, 6.4%, and 6.6% of the Flu-25, Flu-50, and control group, respectively. Reactogenicity/safety endpoints were within the same range for all vaccines. In children aged 6-35 months, immune responses with Flu-50 fulfilled regulatory criteria but did not meet the predefined criteria for non-inferiority vs. control. This appeared to be due to differences in immunogenicity in children aged <18 months. ? 2013 Landes Bioscience. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84884640989&doi=10.4161%2fhv.25363&partnerID=40&md5=b4f34f6a06c5c9d0c52fba77732d6694 https://scholars.lib.ntu.edu.tw/handle/123456789/566455 |
ISSN: | 2164-5515 | DOI: | 10.4161/hv.25363 | SDG/關鍵字: | influenza vaccine; allergic rhinitis; anemia; apnea; article; asthma; bronchiolitis; child; child health care; chronic disease; clinical effectiveness; clinical evaluation; controlled study; cyanosis; dose response; drowsiness; drug dose comparison; drug efficacy; drug safety; female; fever; gastroenteritis; hemagglutination inhibition; human; immune response; immunogenicity; infant; infection prevention; influenza vaccination; injection site pain; injection site swelling; irritability; loss of appetite; male; pneumonia; preschool child; randomized controlled trial; seasonal influenza; seroconversion; side effect; skin redness; treatment outcome; upper respiratory tract infection; children; immunogenicity; influenza; trivalent inactivated; vaccine; Antibodies, Viral; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Female; Hemagglutination Inhibition Tests; Humans; Infant; Influenza Vaccines; Influenza, Human; Male; Vaccination; Vaccines, Inactivated |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。